NASDAQ:CBLI

Cleveland BioLabs Stock Forecast, Price & News

$3.55

-0.10 (-2.74 %)

(As of 01/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$3.49

Now: $3.55▼

$3.74

50-Day Range

$2.71

MA: $3.30▼

$3.94

52-Week Range

$0.80

Now: $3.55▼

$5.43

Volume252,024 shs

Average Volume230,720 shs

Market Capitalization$47.34 million

P/E RatioN/A

Dividend YieldN/A

Beta0.61

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, and Everon Biosciences. The company was founded in 2003 and is headquartered in Buffalo, New York.

MarketRank^™

Overall MarketRank^™

0.64 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Cleveland BioLabs.

3.2 Community Rank

Outperform Votes
Cleveland BioLabs has received 276 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Cleveland BioLabs has received 155 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Cleveland BioLabs has received 64.04% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Cleveland BioLabs and other stocks. Vote “Outperform” if you believe CBLI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CBLI will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Cleveland BioLabs does not currently pay a dividend.
Dividend Growth
Cleveland BioLabs does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cleveland BioLabs insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.03% of the stock of Cleveland BioLabs is held by insiders.
Percentage Held by Institutions
Only 2.59% of the stock of Cleveland BioLabs is held by institutions.

0.0 Earnings and Valuation

Price to Book Value per Share Ratio
Cleveland BioLabs has a P/B Ratio of 39.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Commercial physical research

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CBLI

Previous Symbol

CUSIPN/A

CIK1318641

Webwww.cbiolabs.com

Phone716-849-6810

Employees7

Debt

Debt-to-Equity RatioN/A

Current Ratio6.66

Quick Ratio6.66

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$1.11 million

Price / Sales42.65

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.09 per share

Price / Book39.44

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-2,650,000.00

Net Margins-382.26%

Return on Equity-123.97%

Return on Assets-86.26%

Miscellaneous

Outstanding Shares13,336,000

Market Cap$47.34 million

Next Earnings DateN/A

OptionableNot Optionable

$3.55

-0.10 (-2.74 %)

(As of 01/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive CBLI News and Ratings via Email

Sign-up to receive the latest news and ratings for CBLI and its competitors with MarketBeat's FREE daily newsletter.

Cleveland BioLabs (NASDAQ:CBLI) Frequently Asked Questions

How has Cleveland BioLabs' stock been impacted by COVID-19 (Coronavirus)?

Cleveland BioLabs' stock was trading at $3.15 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CBLI stock has increased by 12.7% and is now trading at $3.55.
View which stocks have been most impacted by COVID-19.

What stocks does MarketBeat like better than Cleveland BioLabs?

Wall Street analysts have given Cleveland BioLabs a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cleveland BioLabs wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Cleveland BioLabs' earnings last quarter?

Cleveland BioLabs, Inc. (NASDAQ:CBLI) issued its quarterly earnings results on Friday, May, 15th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $0.16 million for the quarter. Cleveland BioLabs had a negative return on equity of 123.97% and a negative net margin of 382.26%.
View Cleveland BioLabs' earnings history.

Who are some of Cleveland BioLabs' key competitors?

Some companies that are related to Cleveland BioLabs include Auxly Cannabis Group (CBWTF), Bioanalytical Systems (BASI), Eloxx Pharmaceuticals (ELOX), Pieris Pharmaceuticals (PIRS), AIkido Pharma (AIKI), NanoViricides (NNVC), ProMIS Neurosciences (ARFXF), Tenax Therapeutics (TENX), Inhibitor Therapeutics (INTI), HedgePath Pharmaceuticals (HPPI), U.S. Stem Cell (USRM), Vitality Biopharma (VBIO), DNAPrint Genomics (DNAG), Affinity Energy and Health (ALGXY) and Bioqual (BIOQ).
View all of CBLI's competitors.

What other stocks do shareholders of Cleveland BioLabs own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cleveland BioLabs investors own include iBio (IBIO), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Novavax (NVAX), Biocept (BIOC) and Co-Diagnostics (CODX).

Who are Cleveland BioLabs' key executives?

Cleveland BioLabs' management team includes the following people:

Mr. Christopher Zosh, VP of Fin., Interim Principal Exec. Officer, Principal Financial Officer & Accounting Officer (Age 46, Pay $103.49k)
Dr. Andrei V. Gudkov, Chief Scientific Officer (Age 65, Pay $66.14k)
Dr. Langdon L. Miller, Chief Medical Officer (Age 67, Pay $73.72k)

What is Cleveland BioLabs' stock symbol?

Cleveland BioLabs trades on the NASDAQ under the ticker symbol "CBLI."

How do I buy shares of Cleveland BioLabs?

Shares of CBLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cleveland BioLabs' stock price today?

One share of CBLI stock can currently be purchased for approximately $3.55.

How big of a company is Cleveland BioLabs?

Cleveland BioLabs has a market capitalization of $47.34 million and generates $1.11 million in revenue each year. Cleveland BioLabs employs 7 workers across the globe.

What is Cleveland BioLabs' official website?

The official website for Cleveland BioLabs is www.cbiolabs.com.

How can I contact Cleveland BioLabs?

Cleveland BioLabs' mailing address is 73 HIGH STREET, BUFFALO NY, 14203. The biotechnology company can be reached via phone at 716-849-6810 or via email at [email protected]

This page was last updated on 1/18/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Cleveland BioLabs Stock Forecast, Price & News

Adding

Adding

Adding Cleveland BioLabs, Inc.

MarketRank™

Overall MarketRank™